Chongqing Genrix Biopharmaceutical Co has a Cash Ratio of 22.97. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Chongqing Genrix Biopharmaceutical Co Cash Ratio Chart
Chongqing Genrix Biopharmaceutical Co Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Cash Ratio
0.05
0.12
5.13
2.27
21.33
Chongqing Genrix Biopharmaceutical Co Quarterly Data
Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Cash Ratio
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co's Cash Ratio Distribution in the Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Chongqing Genrix Biopharmaceutical Co Cash Ratio Related Terms
Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:688443 has been successfully added to your 